Pamela Munster
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pamela Munster sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Pamela Munster: 5 sponsored US clinical trials, 1 recruiting.
Pamela Munster sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Checkpoint Kinase 2 Gene Mutation, with 1 trials.
Upper-quartile sponsor footprint
Pamela Munster sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
NCT06177171
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
NCT03318445
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
NCT02620839
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
NCT02358200
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
NCT01543763
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
What is open in the Pamela Munster pipeline
1 recruiting of 5 indexed (20% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Checkpoint Kinase 2 Gene Mutation (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pamela Munster: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Pamela Munster sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Pamela Munster page
5 registered trials is a research-attention snapshot, not an endorsement of Pamela Munster or any single study.
- 1 of Pamela Munster's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Checkpoint Kinase 2 Gene Mutation is the condition Pamela Munster studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Checkpoint Kinase 2 Gene Mutation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pamela Munster pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.